Neuren Pharmaceuticals Ltd. (NURPF)
12.88
0.00 (0.00%)
USD |
OTCM |
Dec 10, 16:00
Price Chart
Key Stats
| Price and Performance | |
|---|---|
| Market Cap | 1.627B |
| 52 Week High (Daily) | Upgrade |
| 52 Week Low (Daily) | Upgrade |
| All-Time High (Daily) | Upgrade |
| Year to Date Total Returns (Daily) | Upgrade |
| 1 Month Total Returns (Daily) | Upgrade |
| 1 Year Total Returns (Daily) | 61.06% |
| Valuation | |
| PE Ratio | 17.15 |
| PE Ratio (Forward) | Upgrade |
| PS Ratio | 11.72 |
| Price to Book Value | -- |
| EV to EBITDA | Upgrade |
| Dividend | |
|---|---|
| Dividend | -- |
| Dividend Yield (Forward) | Upgrade |
| Financials | |
| Revenue (5 Year Growth) | Upgrade |
| Revenue (Quarterly YoY Growth) | Upgrade |
| EPS Diluted (5 Year Growth) | Upgrade |
| EPS Diluted (Quarterly YoY Growth) | Upgrade |
| Debt to Equity Ratio | -- |
| Return on Equity | Upgrade |
| Return on Assets | Upgrade |
| Risk | |
| Beta (5Y) | Upgrade |
| Max Drawdown (5Y) | 67.76% |
Profile
| Neuren Pharmaceuticals Ltd. engages in the development of new therapies for neurodevelopmental disorders that emerge in early childhood. It operates through the Commercial Products, and Research and Development segments. The Commercial Products segment refers to the milestone and royalty revenue from license of intellectual property. The Research and Development segment focuses on the development of pharmaceutical products for the treatment of neurodevelopmental disorders. The company was founded on December 17, 2001 and is headquartered in Camberwell, Australia. |
| URL | http://www.neurenpharma.com |
| Investor Relations URL | N/A |
| HQ State/Province | Victoria (VIC) |
| Sector | Health Care |
| Industry | Pharmaceuticals |
| Next Earnings Release | N/A |
| Last Earnings Release | N/A |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |
Ratings
Profile
| Neuren Pharmaceuticals Ltd. engages in the development of new therapies for neurodevelopmental disorders that emerge in early childhood. It operates through the Commercial Products, and Research and Development segments. The Commercial Products segment refers to the milestone and royalty revenue from license of intellectual property. The Research and Development segment focuses on the development of pharmaceutical products for the treatment of neurodevelopmental disorders. The company was founded on December 17, 2001 and is headquartered in Camberwell, Australia. |
| URL | http://www.neurenpharma.com |
| Investor Relations URL | N/A |
| HQ State/Province | Victoria (VIC) |
| Sector | Health Care |
| Industry | Pharmaceuticals |
| Next Earnings Release | N/A |
| Last Earnings Release | N/A |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |